The Global Neurodiagnostics Market is driven by growing prevalence...

The Global Neurodiagnostics Market is driven by growing prevalence of neurological disorders

Postado 2024-04-18 14:28:01

The neurodiagnostics market consists of devices and tests that are used to identify various neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, cancer, stroke, and epilepsy. Imaging tests such as MRI (Magnetic Resonance Imaging) and CT (Computed Tomography) scans provide physicians with detailed images of the brain and spinal cord. Neurological biomarkers testing identifies molecular and genetic markers associated with neurological conditions. Neurological monitoring devices aid in detecting brain activity during neurological procedures. The neurodiagnostics market helps physicians accurately diagnose neurological disorders and aids in the clinical management and treatment of patients.

The Global Neurodiagnostics Market is estimated to be valued at US$ 14.91 Bn in 2024 and is expected to exhibit a CAGR of 8.1% over the forecast period from 2024 to 2031.

Key Takeaways
Key players operating in the neurodiagnostics market are Koninklijke Philips N.V, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corporation, Bio-Rad Laboratories Inc., Advanced Brain Monitoring, Inc., Nihon Kohden Corporation, Mitsar Co. LTD., EMS Biomedical, Mennen Medical, Natus Medical Incorporated, Medicaid Systems, Fujirebio, FONAR Corp, ANT Neuro, NEUROLITE AG, and Atlantic Health System. These companies offer advanced imaging systems, neurological monitoring devices, and neurological biomarkers tests for the clinical diagnosis of various neurological disorders.

The growing prevalence of neurological disorders across the world due to increasingly unhealthy lifestyles and an aging global population is expected to drive the demand for Neurodiagnostics Market Demand procedures. According to the World Health Organization, neurological disorders affect over a billion people globally with Alzheimer's disease and dementia being the most common. Increasing healthcare spending on advanced diagnostic technologies to reduce healthcare costs associated with the treatment of chronic neurological conditions will further augment the growth of the neurodiagnostics market.

Get more insights, On Neurodiagnostics Market